<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35583021</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>19</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>19</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0040-5930</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>79</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Therapeutische Umschau. Revue therapeutique</Title>
          <ISOAbbreviation>Ther Umsch</ISOAbbreviation>
        </Journal>
        <ArticleTitle>[IgA vasculitis - similarities and differences to IgA nephropathy].</ArticleTitle>
        <Pagination>
          <StartPage>260</StartPage>
          <EndPage>268</EndPage>
          <MedlinePgn>260-268</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1024/0040-5930/a001359</ELocationID>
        <Abstract>
          <AbstractText>IgA vasculitis - similarities and differences to IgA nephropathy <b>Abstract.</b> IgA vasculitis (IgAV), formerly called Henoch-Schönlein Purpura (HSP) is an immune complex-mediated vasculitis of small vessels typically affecting the skin, gastrointestinal tract, and the kidneys. Based on distinct histopathological and pathophysiological commonalities of IgAV and IgA nephropathy (IgAN) they are viewed as part of a spectrum of IgA-mediated inflammatory syndromes. While the disease course in children is most often benign, IgAV has a high risk of renal and gastrointestinal complications when first appearing in adulthood. Acute morbidity and mortality in IgAV are determined by gastrointestinal complications such as intussusception or perforation, while chronic morbidity depends on renal involvement. Nephritis symptoms can appear, subclinically, many weeks after the initial manifestation of IgAV, and can therefore be missed. Continuous monitoring of renal parameters and blood pressure is therefore recommended even after apparent remission of the disease. As there are no data from randomized controlled trials available, the treatment of IgAV is currently based on consensus-based expert opinions.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Gadola</LastName>
            <ForeName>Stephan Donat</ForeName>
            <Initials>SD</Initials>
            <AffiliationInfo>
              <Affiliation>Klinik Rheumatologie &amp; Schmerzmedizin, Bethesda Spital Basel.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>ger</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <VernacularTitle>Die IgA-Vaskulitis.</VernacularTitle>
      </Article>
      <MedlineJournalInfo>
        <Country>Switzerland</Country>
        <MedlineTA>Ther Umsch</MedlineTA>
        <NlmUniqueID>0407224</NlmUniqueID>
        <ISSNLinking>0040-5930</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005922" MajorTopicYN="Y">Glomerulonephritis, IGA</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011695" MajorTopicYN="Y">IgA Vasculitis</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007668" MajorTopicYN="N">Kidney</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009393" MajorTopicYN="Y">Nephritis</DescriptorName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012867" MajorTopicYN="N">Skin</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <OtherAbstract Type="Publisher" Language="ger">
        <AbstractText><b>Zusammenfassung.</b> Die IgA-Vaskulitis (IgAV) ist eine Immunkomplexvaskulitis kleiner Gefässe, welche typischerweise in Form einer leukozytoklastischen Hautvaskulitis mit palpabler Purpura sowie Abdominalschmerzen und Nephritis in Erscheinung tritt. Die IgAV weist markante Gemeinsamkeiten der Pathophysiologie und renalen Histopathologie mit der IgA-Nephropathie auf, weshalb diese Erkrankungen einem gemeinsamen Spektrum IgA-vermittelter Syndrome zugeordnet werden können. Bei Kindern ist die IgAV (Henoch-Schönlein-Purpura, HSP) häufig spontan regredient, während sie bei Erwachsenen öfter einen schwereren Verlauf nimmt. Die akute Prognose wird hauptsächlich durch die Beteiligung des Gastrointestinaltrakts, und der Langzeitverlauf durch die renale Beteiligung bestimmt. Da der Nierenbefall verzögert auftreten kann, sind regelmässige Kontrollen der Nierenparameter auch nach scheinbarer klinischer Remission sinnvoll. Aktuelle Empfehlungen zur medikamentösen Behandlung der IgAV basieren auf konsensusbasierten Expertenmeinungen da noch keine randomisierten kontrollierten Studien zur Verfügung stehen.</AbstractText>
      </OtherAbstract>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>18</Day>
          <Hour>5</Hour>
          <Minute>33</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35583021</ArticleId>
        <ArticleId IdType="doi">10.1024/0040-5930/a001359</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
